Trial Profile

Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cilgavimab/tixagevimab (Primary) ; Hydroxychloroquine (Primary) ; Interferon beta-1a (Primary) ; Interferon beta-1a (Primary) ; Lopinavir/ritonavir (Primary) ; Lopinavir/ritonavir (Primary) ; Remdesivir (Primary)
Indications COVID-19 respiratory infection
Focus Registrational; Therapeutic Use
Acronyms DisCoVeRy
Sponsors INSERM

Most Recent Events

08 Apr 2025 According to an AstraZeneca media release, data from this trial will be presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria.
05 Apr 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
24 Nov 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com